Trial Profile
A Randomized, Double-blind, Single Dose Crossover Study to Assess the Effect of Gabapentin Enacarbil on Cardiac Conduction as Compared With Placebo and Moxifloxacin in Healthy Volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Dec 2023
Price :
$35
*
At a glance
- Drugs Gabapentin enacarbil (Primary) ; Moxifloxacin
- Indications Diabetic neuropathies; Postherpetic neuralgia; Restless legs syndrome
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK; XenoPort
- 25 Mar 2013 Lead trial centre amended as reported by ClinicalTrials.gov.
- 12 Apr 2012 Actual end date (March 2012) added as reported by ClinicalTrials.gov.
- 12 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.